Form 4: Cytokinetics EVP Fady Ibraham Malik Reports Stock Transactions
SEC Form 4
EVP of Research & Development at Cytokinetics, Fady Ibraham Malik, reports the acquisition and disposal of common stock and derivative securities.
Summary
- On February 18, 2025, Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc., reported transactions involving Cytokinetics' common stock and non-qualified stock options.
- Malik acquired 2,000 shares of common stock at a price of $10.6 per share and disposed of 2,000 shares at $45.98 per share.
- These transactions were related to the exercise of non-qualified stock options.
- Following these transactions, Malik directly owns 116,071 shares of Cytokinetics' common stock and 33,105 non-qualified stock options.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel and their holdings in the company.
Stakeholder Impact
- The transactions may be of interest to shareholders as they provide insight into management's perspective on the company's stock value.
Key Dates
| Date | Description |
|---|---|
| 03/28/2017 | Date exercisable for Non-Qualified Stock Option (Right to Buy) |
| 02/28/2027 | Expiration date for Non-Qualified Stock Option (Right to Buy) |
| 02/18/2025 | Date of transaction and signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.